Clinic
Monongalia County General Hospital Company
Monongalia County General Hospital Company was paid $16.36M by Medicaid between Jan 2018 and Dec 2024, across 224 billing codes. Its largest line is 99284, emergency room visit (serious) — 14% of everything it billed.
33Billing provider infoMONONGALIA COUNTY GENERAL HOSPITAL COMPANY
MORGANTOWN, WV 26505
MORGANTOWN, WV 26505
33aNPI1659489631assigned 08/29/2006
33bProvider typeClinic/Center
28Total paid$16.36M
24GClaims413,320
24DCodes billed224
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinic/Center providers in West Virginia
Rank by total paid#2 of 20
Median peer was paid$667K
This provider vs. median25×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 60,041 | $5.40M | |
| 2019 | 33,646 | $2.43M | |
| 2020 | 76,457 | $4.11M | |
| 2021 | 97,774 | $1.68M | |
| 2022 | 55,056 | $986K | |
| 2023 | 51,121 | $957K | |
| 2024incomplete | 39,225 | $787K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 15,297 | 12,952 | $2.27M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.1% | 3,685 | 3,098 | $1.32M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.0% | 14,535 | 12,883 | $1.31M |
| 80053 | Comprehensive metabolic panel | 4.1% | 28,395 | 22,928 | $678K |
| 36415 | Collection of venous blood by venipuncture | 4.0% | 35,705 | 25,635 | $658K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.1% | 27,939 | 22,062 | $514K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.1% | 1,967 | 1,670 | $506K |
| 41899 | Unlisted procedure, dentoalveolar structures | 2.5% | 533 | 468 | $414K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.3% | 9,141 | 7,636 | $373K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.1% | 1,614 | 1,397 | $351K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 1.9% | 7,346 | 5,820 | $310K |
| G0378 | Hospital observation service, per hour | 1.8% | 2,872 | 1,467 | $299K |
212 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.8% | 3,201 | $298K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.6% | 3,299 | $254K |
| 85027 | 1.4% | 10,091 | $230K | |
| 84703 | 1.2% | 3,913 | $202K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.2% | 11,357 | $193K |
| 84484 | 1.2% | 6,869 | $191K | |
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 1,360 | $191K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.1% | 3,716 | $182K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.1% | 6,168 | $180K |
| 83735 | 1.1% | 7,865 | $178K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 6,491 | $175K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.0% | 6,572 | $169K |
| 81001 | <1% | 12,233 | $162K | |
| 82962 | <1% | 3,661 | $159K | |
| 83690 | <1% | 5,198 | $153K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,486 | $151K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,165 | $142K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 10,557 | $139K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,010 | $132K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,589 | $128K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,362 | $117K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,767 | $115K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 912 | $104K |
| 87088 | <1% | 4,844 | $104K | |
| 85610 | <1% | 4,778 | $102K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 226 | $102K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,995 | $101K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,897 | $100K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 423 | $92K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,490 | $88K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,834 | $86K |
| 85730 | <1% | 3,891 | $86K | |
| 81003 | <1% | 2,675 | $81K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,108 | $80K |
| 86850 | <1% | 3,504 | $76K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,513 | $72K |
| 87631 | <1% | 562 | $71K | |
| 80061 | Lipid panel | <1% | 4,041 | $70K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,390 | $67K |
| 88142 | <1% | 2,638 | $62K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,760 | $61K |
| 86900 | <1% | 2,710 | $60K | |
| 83605 | <1% | 2,738 | $57K | |
| 88300 | <1% | 363 | $56K | |
| 87040 | <1% | 1,301 | $56K | |
| 82150 | <1% | 688 | $55K | |
| 82565 | <1% | 1,307 | $53K | |
| 74018 | <1% | 910 | $53K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 406 | $51K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 201 | $51K |
| 86901 | <1% | 2,735 | $49K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,998 | $48K |
| 82550 | <1% | 1,618 | $47K | |
| 88307 | <1% | 251 | $46K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 188 | $43K |
| 82553 | <1% | 653 | $41K | |
| 87077 | <1% | 1,927 | $41K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 968 | $39K |
| 84439 | <1% | 2,733 | $37K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 210 | $37K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,234 | $37K |
| 93017 | <1% | 262 | $36K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,547 | $35K |
| 99152 | <1% | 633 | $33K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 415 | $33K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,151 | $32K |
| 87186 | <1% | 1,629 | $30K | |
| 86803 | <1% | 1,715 | $30K | |
| 88312 | <1% | 599 | $30K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 417 | $27K |
| 96367 | <1% | 322 | $26K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 482 | $25K |
| 83880 | <1% | 1,076 | $23K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 16 | $23K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 232 | $22K |
| 88342 | <1% | 75 | $21K | |
| 80050 | General health panel | <1% | 1,259 | $21K |
| 87340 | <1% | 1,461 | $20K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 396 | $19K |
| 87150 | <1% | 483 | $18K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,195 | $17K |
| 84702 | <1% | 816 | $17K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 400 | $17K |
| 87070 | <1% | 638 | $16K | |
| 80329 | <1% | 851 | $15K | |
| 86762 | <1% | 723 | $15K | |
| 96376 | <1% | 630 | $14K | |
| 87641 | <1% | 266 | $14K | |
| 86592 | <1% | 969 | $14K | |
| 87430 | <1% | 267 | $13K | |
| 83615 | <1% | 342 | $13K | |
| 93458 | <1% | 48 | $12K | |
| 93971 | <1% | 178 | $12K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 123 | $12K |
| 85379 | <1% | 478 | $12K | |
| 82607 | <1% | 885 | $11K | |
| 85652 | <1% | 1,030 | $10K | |
| 71250 | <1% | 74 | $10K | |
| 73630 | <1% | 247 | $9K | |
| 73564 | <1% | 88 | $9K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 160 | $8K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 430 | $8K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 338 | $7K |
| 86140 | <1% | 1,148 | $7K | |
| 81025 | <1% | 446 | $7K | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,453 | $7K |
| 82947 | <1% | 557 | $6K | |
| 72110 | <1% | 89 | $6K | |
| 88304 | <1% | 84 | $5K | |
| 76830 | Ultrasound, transvaginal | <1% | 47 | $5K |
| 93296 | <1% | 559 | $5K | |
| 82728 | <1% | 428 | $5K | |
| 73130 | <1% | 178 | $4K | |
| 93880 | <1% | 26 | $4K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 130 | $4K |
| 83540 | <1% | 503 | $4K | |
| 0100U | <1% | 55 | $4K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 117 | $4K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,797 | $4K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 130 | $4K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,121 | $4K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 69 | $4K |
| 82378 | <1% | 79 | $4K | |
| 76642 | <1% | 41 | $3K | |
| 59025 | Fetal non-stress test | <1% | 321 | $3K |
| 87481 | <1% | 127 | $3K | |
| 86304 | <1% | 140 | $3K | |
| 73610 | <1% | 85 | $3K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 15 | $3K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 58 | $3K |
| 83550 | <1% | 285 | $3K | |
| 80143 | <1% | 228 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 413 | $2K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 171 | $2K |
| 87081 | <1% | 162 | $2K | |
| 88112 | <1% | 13 | $2K | |
| 86308 | <1% | 53 | $2K | |
| 93000 | <1% | 25 | $1K | |
| 84550 | <1% | 66 | $1K | |
| 73030 | <1% | 73 | $1K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,245 | $1K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,180 | $1K |
| 82784 | <1% | 90 | $1K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 688 | $962.05 |
| 94760 | <1% | 40 | $958.61 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,208 | $890.00 |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 13 | $878.70 |
| 84100 | <1% | 163 | $757.18 | |
| 36600 | <1% | 16 | $687.37 | |
| 82803 | <1% | 15 | $669.36 | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 13 | $653.17 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 526 | $630.35 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,787 | $618.82 |
| 86922 | <1% | 14 | $612.66 | |
| 84153 | <1% | 28 | $577.79 | |
| 84450 | <1% | 120 | $526.22 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 85 | $485.92 |
| 83001 | <1% | 12 | $457.75 | |
| C1769 | Guide wire | <1% | 915 | $450.44 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 35 | $415.85 |
| 84460 | <1% | 98 | $413.77 | |
| 86038 | <1% | 47 | $393.29 | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 15 | $376.81 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 3,173 | $364.17 |
| 87076 | <1% | 43 | $354.18 | |
| 83516 | <1% | 15 | $352.91 | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 17 | $343.40 |
| 86709 | <1% | 48 | $336.80 | |
| 80076 | <1% | 66 | $332.48 | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 36 | $318.41 |
| 82043 | <1% | 100 | $317.18 | |
| 82746 | <1% | 32 | $305.79 | |
| 84403 | <1% | 17 | $301.99 | |
| 94060 | <1% | 12 | $299.16 | |
| G0008 | Administration of influenza virus vaccine | <1% | 12 | $287.58 |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 12 | $271.81 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 25 | $264.84 |
| 97161 | <1% | 16 | $264.12 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 556 | $262.72 |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 12 | $256.25 |
| 84402 | <1% | 13 | $252.12 | |
| 76937 | <1% | 43 | $234.31 | |
| 86618 | <1% | 17 | $183.96 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 177 | $177.64 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 743 | $169.80 |
| 86705 | <1% | 17 | $148.26 | |
| 87590 | <1% | 13 | $148.15 | |
| 86255 | <1% | 17 | $141.05 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 30 | $136.67 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 252 | $122.88 |
| 86706 | <1% | 13 | $101.73 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 29 | $79.66 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 99 | $76.38 |
| 86430 | <1% | 13 | $55.30 | |
| 36591 | <1% | 77 | $52.38 | |
| 96523 | <1% | 36 | $31.34 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 64 | $26.88 |
| 85018 | <1% | 17 | $21.36 | |
| 85014 | <1% | 17 | $21.36 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,451 | $17.17 |
| 85347 | <1% | 14 | $11.55 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 66 | $9.53 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,018 | $2.90 |
| 81015 | <1% | 25 | $1.09 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 166 | $0.43 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 626 | $0.00 |
| J3490 | Unclassified drugs | 0% | 73 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 162 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 31 | $0.00 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 0% | 15 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 202 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSCHERICH, CLYDE (VP OF FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Monongalia County General Hospital Company | Morgantown, WV | $6.82M |
| Mon Health Marion Neighborhood Hospital, INC. | White Hall, WV | $1.03M |
| Monongalia County General Hospital Company | Morgantown, WV | $345K |
| Monongalia County General Hospital Company | Mannington, WV | $43K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.